U.S. biotechnology company Moderna expects results from its clinical trial of coronavirus vaccine for children ages two to five as early as March.
If the data and discussions with regulators were positive, Moderna could then seek emergency approval for the vaccine, the company announced Wednesday.
“In the first half of 2022”
The other makers of an mRNA vaccine, Biontech and Pfizer, had said in mid-December they expected to seek emergency approval for ages six months to five years “in the first half of 2022.”
The Biontech-Pfizer product is already approved in the U.S. by the Food and Drug Administration (FDA) for children five years of age and older, but the vaccines from Moderna and Johnson & Johnson have so far only been approved for adults.
Moderna had already applied for emergency approval in the U.S. for the age group from twelve to 18. However, the FDA requested additional data from the manufacturer in October and has not yet ruled on the application.
This post has already been read 21 times!